Apr 06, 2021 / 09:00PM GMT
Operator
Good day, and thank you for standing by. Welcome to the FibroGen Provides Roxadustat Update Call. (Operator Instructions) And please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference to your speaker today, Michael Tung. Please go ahead.
Michael Tung - FibroGen, Inc. - IR Executive
Thank you, Victor. Good afternoon, everyone. I'm Michael Tung, Vice President of Corporate Strategy and Investor Relations at FibroGen. Joining me on today's call are Enrique Conterno, our Chief Executive Officer; and Dr. Mark Eisner, our Chief Medical Officer. Format for today's call includes prepared remarks from Enrique and Mark. After which, we will open up the call for Q&A.
I would like to remind you that remarks made on today's call include forward-looking statements about FibroGen. Such statements may include, but are not limited to, statements regarding our collaboration with AstraZeneca and Astellas; results of clinical trials; our regulatory strategies and potential regulatory results; commercial
FibroGen Inc Provides Additional Information on Roxadustat - Conference Call Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers